Skip to main content

Table 2 Median age of patients 48.5 (3–71)

From: Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response

Patient ID

Age

Gender

Performance status

Diagnoses

Number of vaccinations

Time to progression (Weeks)

Survival (Weeks)

Maximum related toxicity/grade

Response status

Patient 1

71

Male

80

GBM

2

4.2

34.6

ISR/1

Non-stable

Patient 2

61

Male

90

GBM

4

8

12.4

 

Non-stable

Patient 3

42

Female

80

GBM

I

Not evaluable

N/A

 

Non-stable

Patient 4

55

Female

90

GBM

5

13.0

64.8

ISR/ 1

Stable

Patient 5

17

Male

70

GBM

10

30.6

53.3

lSR/1

Stable

Patient 6

63

Male

90

GBM

9

39.7

>92

ISR/1

Stable

Patient 7

3

Female

60

Epend

6

20.0

31.4

Fat/i

 

ISR/3

Stable

        

Patient 8

24

Female

90

Med

5

8.0

>92

 

Non-stable

Patient 9

53

Male

80

GBM

0

N/A

N/A

 

Non-stable

Patient 10

13

Female

90

PNET

0

N/A

N/A

 

Non-stable

Patient 11

49

Male

80

GBM

0

N/A

N/A

 

Non-stable

Patient 12

48

Male

80

GBM

0

N/A

N/A

 

Non-stable

  1. Male: Female 4:4. prior treatment regimes median (range) 1.5 (1–4). Performance Status (KPSansky), GBM Glioblastoma (WHO Grade IV), Epend = Ependymoma. Med = Medloblastoma, PNRT = primitive neuroectodemial tumor. ISR = Injection site skin reaction. Fat = Fatigue. Survival is measured in weeks post treatment Patients 9–12 failed trial prior to vaccination.